Arris, SmithKline deal

The companies will explore the application of ARRS's Delta technology to intracellular antiviral protease targets. The agreement includes a proof-of-concept phase followed with an R&D collaboration. ARRS will receive an undisclosed commitment fee and R&D support, and be eligible for milestones and royalties. ...